Sara Coca Membribes· @scocmem · X·· 19 hours agoScore70
Body
#ESMO26 WUTSUP-02 exploring DV + tislelizumab (PD-1) in high-risk UTUC shows pCR 28% and higher responses in HER2 2+ & 3+
Still need to better understand the role of HER2 as a biomarker here, given the activity seen in HER2-low metastatic disease
@OncoAlert
13 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA79matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgSource: Sara Coca Membribes · x.com